Department of Anaesthesiology, Copenhagen University Hospital-North Zealand, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Acta Anaesthesiol Scand. 2021 Oct;65(9):1155-1167. doi: 10.1111/aas.13924. Epub 2021 Jun 16.
Precise measurements of fluid status lack valid methods. Bioimpedance is an attractive diagnostic tool because it is noninvasive, quick, and relatively cheap. This systematic review aims to assess the existing evidence of bioimpedance as an accurate measure of fluid status in critically ill patients.
PubMed and Embase up till March 2021 were systematically searched (PROSPERO: CRD42020157436).
Eligibility criteria were studies reporting original data from cohorts of adult patients in intensive care units and doing at least one whole-body bioimpedance and one reference test. In addition, studies assessing internal reproducibility were included.
An extraction form was designed for the purpose.
Nine hundred five studies were screened for eligibility, and 28 studies, comprising 1482 individual patients, were included in the final analysis. Eight studies compared bioimpedance with a gold standard, and two of those reported the results adequate. We found a low mean difference, but the 95% limits of agreements had wide limits. The remaining studies applied different surrogates as reference tests. Correlations ranged from 0.05 to 0.99. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty of evidence for all outcomes was very low.
The accuracy of bioimpedance as a measure for fluids in critically ill patients in the intensive care unit cannot be determined. Due to the lack of a gold standard, numerous studies compared bioimpedance with surrogate outcomes with great variability in both designs and results. Assessing the internal reproducibility of bioimpedance had the same limitations, but the studies overall reported good internal reproducibility.
精确测量液体状态缺乏有效方法。生物阻抗是一种有吸引力的诊断工具,因为它是非侵入性的、快速的,而且相对便宜。本系统评价旨在评估生物阻抗作为重症患者液体状态准确测量的现有证据。
系统检索了PubMed 和 Embase 截至 2021 年 3 月的文献(PROSPERO:CRD42020157436)。
纳入标准为报告 ICU 成年患者队列原始数据并至少进行一次全身生物阻抗和一次参考测试的研究。此外,还纳入了评估内部可重复性的研究。
设计了一个提取表格。
对 905 项研究进行了筛选,最终有 28 项研究,共 1482 名患者纳入最终分析。有 8 项研究将生物阻抗与金标准进行了比较,其中 2 项报告了结果是足够的。我们发现平均差异较小,但 95%一致性界限范围较宽。其余研究应用了不同的替代物作为参考测试。相关性范围从 0.05 到 0.99。所有结局的推荐评估、制定和评估(GRADE)证据确定性均为极低。
无法确定生物阻抗作为 ICU 重症患者液体测量的准确性。由于缺乏金标准,许多研究将生物阻抗与替代结果进行了比较,设计和结果都存在很大的差异。评估生物阻抗的内部可重复性也存在同样的局限性,但总体而言,这些研究报告了良好的内部可重复性。